BioInvent International and Transgene. will present updated data from the Phase I part of the Phase I/IIa study with BT 001 vid European Society for Medical Oncology (ESMO) annual conference in Berlin 17-21 October. BT 001 is an oncolytic virus that expresses an anti-CTLA-4 antibody and is administered in combination with pembrolizumab. The treatment has shown good tolerability and clinical responses in two of six refractory patients.
|
Published July 28, 2025
BioInvent presents BT-001 data at ESMO
Notes
Johnson & Johnson acquires Halda Therapeutics for $3 billion
Magle Group submits application for EmboCept S
Quia Pharma is delisted from Nasdaq
Stenocare acquires CannGros
Lundbeck enters the fight for Avadel
Klaria's partner CNX starts production of migraine film
Sofinnova Partners raises EUR 650 million in new fund
NEWSLETTER
Today's news roundup
News roundup Monday, November 17
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Pila Pharma stands out in next-generation obesity pipeline
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
SwedenBIO wants to give growth power to the industry
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account